BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 12456207)

  • 1. Practice patterns of testing waived under the clinical laboratory improvement amendments.
    Steindel SJ; Granade S; Lee J; Avery G; Clarke LM; Jenny RW; LaBeau KM
    Arch Pathol Lab Med; 2002 Dec; 126(12):1471-9. PubMed ID: 12456207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Good laboratory practices for waived testing sites: survey findings from testing sites holding a certificate of waiver under the clinical laboratory improvement amendments of 1988 and recommendations for promoting quality testing.
    Howerton D; Anderson N; Bosse D; Granade S; Westbrook G
    MMWR Recomm Rep; 2005 Nov; 54(RR-13):1-25; quiz CE1-4. PubMed ID: 16280973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2012 Apr; 61(RR-2):1-44. PubMed ID: 22475884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good laboratory practices for molecular genetic testing for heritable diseases and conditions.
    Chen B; Gagnon M; Shahangian S; Anderson NL; Howerton DA; Boone JD;
    MMWR Recomm Rep; 2009 Jun; 58(RR-6):1-37; quiz CE-1-4. PubMed ID: 19521335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality control of test systems waived by the Clinical Laboratory Improvement Amendments of 1988. Perceptions and practices.
    LaBeau KM; Simon M; Steindel SJ
    Arch Pathol Lab Med; 2000 Aug; 124(8):1122-7. PubMed ID: 10923070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Common diagnostic tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) in the United States].
    Takemura Y
    Rinsho Byori; 2002 Jan; 50(1):61-7. PubMed ID: 11871138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in physician's office laboratory practices, 1989-1994.
    St John TM; Lipman HB; Krolak JM; Hearn TL
    Arch Pathol Lab Med; 2000 Jul; 124(7):1066-73. PubMed ID: 10888785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)--HCFA. Final rule with comment period.
    Fed Regist; 1992 Feb; 57(40):7002-186. PubMed ID: 10170937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacy-based CLIA-waived testing in the United States: Trends, impact, and the road ahead.
    Zalupski B; Elroumi Z; Klepser DG; Klepser NS; Adams AJ; Klepser ME
    Res Social Adm Pharm; 2024 Jun; 20(6):146-151. PubMed ID: 38519341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.S. community pharmacies as CLIA-waived facilities: Prevalence, dispersion, and impact on patient access to testing.
    Klepser ME; Adams AJ; Srnis P; Mazzucco M; Klepser D
    Res Social Adm Pharm; 2016; 12(4):614-21. PubMed ID: 26508268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final CLIA regulations. Clinical Laboratory Improvement Amendments.
    Health Devices; 1992 Nov; 21(11):420-5. PubMed ID: 1428896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keeping waived tests simple.
    Clin Leadersh Manag Rev; 2004; 18(1):65-9. PubMed ID: 14968759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of CLIA '88 on physician office laboratories.
    Born PH; Thran SL
    J Fam Pract; 1998 Apr; 46(4):319-27. PubMed ID: 9564374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of COVID-19 on prevalence of community pharmacies as CLIA-Waived facilities.
    Klepser NS; Klepser DG; Adams JL; Adams AJ; Klepser ME
    Res Social Adm Pharm; 2021 Sep; 17(9):1574-1578. PubMed ID: 33342702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality assurance in molecular genetic testing laboratories.
    McGovern MM; Benach MO; Wallenstein S; Desnick RJ; Keenlyside R
    JAMA; 1999 Mar; 281(9):835-40. PubMed ID: 10071006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are physicians' office laboratory results of comparable quality to those produced in other laboratory settings?
    Hurst J; Nickel K; Hilborne LH
    JAMA; 1998 Feb; 279(6):468-71. PubMed ID: 9466642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CLIA on physician office laboratories in rural Washington State.
    Roussel PL
    J Fam Pract; 1996 Sep; 43(3):249-54. PubMed ID: 8797752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has compliance with CLIA requirements really improved quality in US clinical laboratories?
    Ehrmeyer SS; Laessig RH
    Clin Chim Acta; 2004 Aug; 346(1):37-43. PubMed ID: 15234634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Inventory of Clinical Laboratory Testing Services (NICLTS). Development and test distribution for 1996.
    Steindel SJ; Rauch WJ; Simon MK; Handsfield J
    Arch Pathol Lab Med; 2000 Aug; 124(8):1201-8. PubMed ID: 10923084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of legislation (CLIA'88) on setting quality specifications for US laboratories.
    Ehrmeyer SS; Laessig RH
    Scand J Clin Lab Invest; 1999 Nov; 59(7):563-7. PubMed ID: 10667700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.